AMRX PDUFA decision: a negative outcome, -8.1%

On August 5, 2022, Amneal Pharmaceuticals, Inc. reached its PDUFA decision. The result was a negative outcome, and the stock moved -8.1% in the window around the event. It had already run +12.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.